United Therapeutics Corporation Payments to Acquire Held-to-maturity Securities
United Therapeutics Corporation (UTHR) reported Payments to Acquire Held-to-maturity Securities of $0 for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireHeldToMaturitySecurities · last filed 2021-02-24
- United Therapeutics Corporation payments to acquire held-to-maturity securities for the quarter ending 2018-12-31 was $35.90M.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for the quarter ending 2018-09-30 was $25.70M, a 3.75% decline year-over-year.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for the quarter ending 2018-06-30 was $10.80M.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for the quarter ending 2018-03-31 was $26.90M, a 7.17% increase year-over-year.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for fiscal 2020 was $0.00.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for fiscal 2018 was $99.30M, a 91.70% increase from fiscal 2017.
- United Therapeutics Corporation payments to acquire held-to-maturity securities for fiscal 2017 was $51.80M, a 6375.00% increase from fiscal 2016.
| Period end | Payments to Acquire Held-to-maturity Securities 3 month | Payments to Acquire Held-to-maturity Securities 3 month as first filed | Payments to Acquire Held-to-maturity Securities 6 month | Payments to Acquire Held-to-maturity Securities 6 month as first filed | Payments to Acquire Held-to-maturity Securities 9 month | Payments to Acquire Held-to-maturity Securities 9 month as first filed | Payments to Acquire Held-to-maturity Securities 12 month | Payments to Acquire Held-to-maturity Securities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2020-12-31 | $0.00 10-K · filed 2021-02-24 | |||||||
| 2019-12-31 | $0.00 10-K · filed 2021-02-24 | |||||||
| 2018-12-31 | $35.90M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $61.60M derived: sum of 2 quarters · filed 2021-02-24 | $72.40M derived: sum of 3 quarters · filed 2021-02-24 | $99.30M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $25.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $36.50M derived: sum of 2 quarters · filed 2019-10-30 | $63.40M 10-Q · filed 2019-10-30 | $63.40M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-06-30 | $10.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $37.70M 10-Q · filed 2019-07-31 | $37.70M derived: sum of 3 quarters · filed 2020-02-26 | $64.40M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | $26.90M 10-Q · filed 2019-05-01 | $26.90M derived: sum of 2 quarters · filed 2020-02-26 | $53.60M derived: sum of 3 quarters · filed 2020-02-26 | $53.60M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $26.70M derived: sum of 2 quarters · filed 2020-02-26 | $26.70M derived: sum of 3 quarters · filed 2020-02-26 | $51.80M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $26.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $26.70M derived: sum of 2 quarters · filed 2018-10-31 | $51.80M 10-Q · filed 2018-10-31 | $51.80M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $25.10M 10-Q · filed 2018-08-01 | $25.10M derived: sum of 3 quarters · filed 2019-02-27 | $25.10M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | $25.10M 10-Q · filed 2018-05-02 | $25.10M derived: sum of 2 quarters · filed 2019-02-27 | $25.10M derived: sum of 3 quarters · filed 2019-02-27 | |||||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 derived: sum of 2 quarters · filed 2019-02-27 | $800.00K 10-K · filed 2019-02-27 | |||||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $800.00K 10-Q · filed 2017-10-25 | ||||||
| 2016-06-30 | $800.00K 10-Q · filed 2017-07-27 | |||||||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | $1.50M derived: sum of 2 quarters · filed 2018-02-21 | $38.50M derived: sum of 3 quarters · filed 2018-02-21 | $62.80M 10-K · filed 2018-02-21 | $62.78M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | $1.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | $38.50M derived: sum of 2 quarters · filed 2016-10-27 | $62.80M 10-Q · filed 2016-10-27 | $62.78M 10-Q · filed 2015-10-27 | $66.33M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $37.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $61.30M 10-Q · filed 2016-07-28 | $61.27M 10-Q · filed 2015-07-28 | $64.83M derived: sum of 3 quarters · filed 2017-02-22 | $69.91M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $24.30M 10-Q · filed 2016-04-28 | $24.26M 10-Q · filed 2015-04-28 | $27.83M derived: sum of 2 quarters · filed 2017-02-22 | $32.91M derived: sum of 3 quarters · filed 2017-02-22 | $32.93M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | $3.53M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $8.61M derived: sum of 2 quarters · filed 2017-02-22 | $8.63M derived: sum of 3 quarters · filed 2017-02-22 | $118.70M 10-K · filed 2017-02-22 | $118.67M 10-K · filed 2015-02-24 | |||
| 2014-09-30 | $5.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $5.10M derived: sum of 2 quarters · filed 2015-10-27 | $115.17M 10-Q · filed 2015-10-27 | $438.74M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-06-30 | $25.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $110.09M 10-Q · filed 2015-07-28 | $433.66M derived: sum of 3 quarters · filed 2016-02-25 | $709.83M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2014-03-31 | $110.07M 10-Q · filed 2015-04-28 | $433.63M derived: sum of 2 quarters · filed 2016-02-25 | $709.81M derived: sum of 3 quarters · filed 2016-02-25 | $760.52M derived: sum of 4 quarters · filed 2016-02-25 | ||||
| 2013-12-31 | $323.56M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $599.74M derived: sum of 2 quarters · filed 2016-02-25 | $650.45M derived: sum of 3 quarters · filed 2016-02-25 | $762.20M 10-K · filed 2016-02-25 | ||||
| 2013-09-30 | $276.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-28 | $326.89M derived: sum of 2 quarters · filed 2014-10-28 | $438.63M 10-Q · filed 2014-10-28 | $669.95M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-06-30 | $50.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-07-29 | $162.46M 10-Q · filed 2014-07-29 | $393.78M derived: sum of 3 quarters · filed 2015-02-24 | $450.36M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2013-03-31 | $111.75M 10-Q · filed 2014-04-29 | $343.06M derived: sum of 2 quarters · filed 2015-02-24 | $399.64M derived: sum of 3 quarters · filed 2015-02-24 | $507.64M derived: sum of 4 quarters · filed 2015-02-24 | ||||
| 2012-12-31 | $231.31M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-24 | $287.90M derived: sum of 2 quarters · filed 2015-02-24 | $395.89M derived: sum of 3 quarters · filed 2015-02-24 | $579.32M 10-K · filed 2015-02-24 | ||||
| 2012-09-30 | $56.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-29 | $164.58M derived: sum of 2 quarters · filed 2013-10-29 | $348.00M 10-Q · filed 2013-10-29 | $547.11M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-06-30 | $107.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-25 | $291.42M 10-Q · filed 2013-07-25 | $490.53M derived: sum of 3 quarters · filed 2014-02-25 | $740.13M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2012-03-31 | $183.42M 10-Q · filed 2013-04-25 | $382.54M derived: sum of 2 quarters · filed 2014-02-25 | $632.13M derived: sum of 3 quarters · filed 2014-02-25 | $825.86M derived: sum of 4 quarters · filed 2014-02-25 | ||||
| 2011-12-31 | $199.11M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $448.71M derived: sum of 2 quarters · filed 2014-02-25 | $642.43M derived: sum of 3 quarters · filed 2014-02-25 | $815.68M 10-K · filed 2014-02-25 | ||||
| 2011-09-30 | $249.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $443.32M derived: sum of 2 quarters · filed 2012-11-01 | $616.57M 10-Q · filed 2012-11-01 | $820.27M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $193.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-26 | $366.98M 10-Q · filed 2012-07-26 | $570.67M derived: sum of 3 quarters · filed 2013-02-26 | $886.61M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $173.25M 10-Q · filed 2012-04-26 | $376.95M derived: sum of 2 quarters · filed 2013-02-26 | $692.88M derived: sum of 3 quarters · filed 2013-02-26 | $763.70M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $203.70M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $519.63M derived: sum of 2 quarters · filed 2013-02-26 | $590.45M derived: sum of 3 quarters · filed 2013-02-26 | $662.23M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $315.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $386.75M derived: sum of 2 quarters · filed 2011-10-27 | $458.53M 10-Q · filed 2011-10-27 | $556.93M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-06-30 | $70.82M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $142.60M 10-Q · filed 2011-07-28 | $241.00M derived: sum of 3 quarters · filed 2012-02-28 | $336.24M derived: sum of 4 quarters · filed 2012-02-28 | ||||
| 2010-03-31 | $71.78M 10-Q · filed 2011-04-28 | $170.18M derived: sum of 2 quarters · filed 2012-02-28 | $265.42M derived: sum of 3 quarters · filed 2012-02-28 | |||||
| 2009-12-31 | $98.40M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-28 | $193.65M derived: sum of 2 quarters · filed 2012-02-28 | $310.63M 10-K · filed 2012-02-28 | |||||
| 2009-09-30 | $95.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | $212.23M 10-Q · filed 2010-10-28 | ||||||
| 2009-06-30 | $116.99M 10-Q · filed 2010-07-28 | |||||||
| 2008-12-31 | $321.36M 10-K · filed 2011-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |